Onselex Welcomes Two Distinguished Medical Innovators to Its Clinical Advisory Board

October 15, 2022

PROMINENT MEDICAL EXPERTS TO GUIDE ONX-1006 TOWARD HUMAN CLINICAL TRIALS FOR PANCREATIC CANCER

Seoul, South Korea, October 6, 2022 — Onselex Inc., a biotechnology company pioneering nanoparticle-based drug delivery technology for cancer and neurological diseases, announced the formation of its Clinical Advisory Board (CAB) with the appointment of two distinguished medical experts.

Joining the Clinical Advisory Board are Professor Si-Young Song, a distinguished professor at Yonsei University and recipient of the Yonsei Medical Grand Award, and Professor Ho-Soon Choi, Vice-Chancellor of Hanyang University Medical Center and a prominent leader in gastrointestinal medicine.

With more than 80 years of combined experience in medicine and cancer treatment, Professor Song and Professor Choi bring extensive clinical expertise to guide the development of ONX-1006, Onselex's nanoparticle-based treatment for pancreatic cancer, as the company advances toward human clinical trials.

Professor Si-Young Song

Professor Si-Young Song graduated from Yonsei University College of Medicine in 1983. Throughout his distinguished career, he has held numerous leadership positions, including Dean of Yonsei University College of Medicine, Dean of the Graduate School of Medicine, and Head of the Yonsei Medical Center Industry-University Cooperation Foundation.

Dr. Song has also served as Chairman of the Korean Health and Medical Technology Policy Review Committee under the Ministry of Health and Welfare, President of the Korean Pancreatobiliary Association, and Chairman of the Korean Society of Gastrointestinal Cancer Research.

In recognition of his outstanding contributions, Professor Song received South Korea's Order of Service Merit, Red Stripes.

Professor Ho-Soon Choi

Professor Ho-Soon Choi is a distinguished physician and medical leader who has served as Vice-Chancellor of Hanyang University Medical Center and Dean of Hanyang University College of Medicine, one of South Korea's leading university medical institutions.

Throughout his career, Dr. Choi has held prominent leadership positions, including Director of the Korean Society of Gastrointestinal Endoscopy, Chairman of the Korean Pancreatobiliary Association, and President of the Korean Society of Internal Medicine.

Advancing ONX-1006 for Pancreatic Cancer

Pancreatic cancer remains one of the most challenging cancers to treat, with limited treatment options and significant toxicity associated with conventional chemotherapy.

Onselex has developed ONX-1006, a nanoparticle-based cancer treatment that carries paclitaxel (PTX), a proven chemotherapy drug, chemically bound to stable nanoparticles designed to concentrate PTX in tumors while protecting normal cells. The company's preclinical research has demonstrated outstanding safety and antitumor efficacy, providing a foundation for advancing ONX-1006 into human clinical trials.

Statement from Onselex's President and CEO

About Onselex

Onselex is a biotechnology company developing innovative nanoparticle-based drug delivery technology for cancer treatment. Its lead drug candidate, ONX-1006, uses paclitaxel (PTX) chemically bound to stable nanoparticles designed to concentrate the chemotherapy drug in tumors while protecting normal cells.

Through its oncology nanomedicine technology, Onselex aims to deliver effective cancer treatment with significantly lower toxicity, protecting patients' quality of life while advancing new therapeutic options for difficult-to-treat cancers.